Streptokinase: Uses, Dosage, Side Effects & Brands | MedexInfo

Streptokinase

Rx

Generic NameStreptokinase

Therapeutic ClassThrombolytic (Fibrinolytic)

Dosage FormInjection (IV infusion)

PregnancyUse only if clearly needed

Indications ▼

Acute ST-Elevation Myocardial Infarction (STEMI): To dissolve coronary thrombus and restore myocardial perfusion when primary PCI is not available.

Pulmonary Embolism (Massive or Submassive): For rapid thrombus dissolution in hemodynamically unstable patients.

Deep Vein Thrombosis (DVT): In selected cases to prevent post-thrombotic complications.

Peripheral Arterial Thrombosis/Embolism: To restore arterial blood flow in acute limb ischemia.

Mechanism & Pharmacokinetics ▼

Mechanism: Forms a complex with plasminogen, converting it into plasmin, which degrades fibrin clots and fibrinogen, leading to thrombus dissolution.

Pharmacokinetics: Administered intravenously. Rapid onset of fibrinolytic action. Half-life approximately 20–30 minutes. Cleared via reticuloendothelial system.

Dosage & Administration ▼

Indication	Dose	Administration
Acute MI	1.5 million IU	IV infusion over 60 minutes
Pulmonary Embolism	250,000 IU loading, then 100,000 IU/hour	Continuous IV infusion for 24 hours
DVT	250,000 IU loading, then 100,000 IU/hour	Continuous IV infusion for 72 hours (as directed)

Note: Administer under strict hospital supervision with monitoring of coagulation parameters and bleeding signs.

Side Effects ▼

Bleeding (major risk)

Hypotension

Allergic reactions (fever, rash)

Anaphylaxis (rare)

Intracranial hemorrhage (rare but serious)

Contraindications ▼

Active internal bleeding

History of hemorrhagic stroke

Recent major surgery or trauma

Severe uncontrolled hypertension

Known hypersensitivity to streptokinase

Drug Interaction ▼

Anticoagulants (heparin, warfarin): increased bleeding risk

Antiplatelet agents (aspirin, clopidogrel): additive bleeding risk

NSAIDs: increased gastrointestinal bleeding risk

Pregnancy & Lactation ▼

Use during pregnancy only if potential benefit justifies risk due to bleeding possibility.

Breastfeeding: Caution advised; limited data available.

Clinical / Research Summary ▼

Clinical Role: Cost-effective thrombolytic agent for acute MI and major thromboembolic events when PCI is unavailable.

Advantage: Widely available and affordable in resource-limited settings.

Limitation: Higher risk of allergic reactions and bleeding compared to newer fibrinolytics.

Monitoring: Blood pressure, coagulation profile, signs of internal or external bleeding.

Patient Counseling Points ▼

Administered in hospital setting only.

Report any unusual bleeding, severe headache, or weakness immediately.

Avoid trauma or invasive procedures during treatment.

Storage & Handling ▼

Store refrigerated at 2–8°C.

Protect from light.

Use reconstituted solution immediately.

Brand Names (Bangladesh & Global) ▼

Bangladesh:

S-Kinase® 1.5 million IU Eptase® 1.5 million IU STK® 1.5 million IU Streptase® 1.5 million IU

Global:

Streptase® Kabikinase®

Medical Disclaimer: For educational purposes only. Not a substitute for professional medical advice.

Reference Hubs:

• Drug Class: Thrombolytics • Condition: Myocardial Infarction • Condition: Pulmonary Embolism • Condition: Deep Vein Thrombosis